Thread regarding Pfizer (PFE)

Unlike Moderna, which continues to diversify its portfolio and has multiple R&D programs in the pipeline, Pfizer is seeing declining sales and facing potential market share losses on several fronts. Demand for its COVID-19 products has been steadily falling, it recently abandoned yet another obesity dr-g development program, and it’s encountering growing competition in marketing its other flagship products. With a possible recession ahead, ongoing supply chain disruptions, and the looming impact of tariffs, it’s time to part ways with Pfizer stock. I plan to sell mine and reallocate the gains into more promising dips.